[go: up one dir, main page]

AU2003270540A1 - Treatment of cyclooxygenase-3 mediated diseases and disorders - Google Patents

Treatment of cyclooxygenase-3 mediated diseases and disorders

Info

Publication number
AU2003270540A1
AU2003270540A1 AU2003270540A AU2003270540A AU2003270540A1 AU 2003270540 A1 AU2003270540 A1 AU 2003270540A1 AU 2003270540 A AU2003270540 A AU 2003270540A AU 2003270540 A AU2003270540 A AU 2003270540A AU 2003270540 A1 AU2003270540 A1 AU 2003270540A1
Authority
AU
Australia
Prior art keywords
cyclooxygenase
disorders
treatment
mediated diseases
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003270540A
Other versions
AU2003270540A8 (en
Inventor
Gordon Letts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitromed Inc
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of AU2003270540A8 publication Critical patent/AU2003270540A8/en
Publication of AU2003270540A1 publication Critical patent/AU2003270540A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003270540A 2002-09-11 2003-09-11 Treatment of cyclooxygenase-3 mediated diseases and disorders Abandoned AU2003270540A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40991302P 2002-09-11 2002-09-11
US60/409,913 2002-09-11
PCT/US2003/028471 WO2004024186A2 (en) 2002-09-11 2003-09-11 Treatment of cyclooxygenase-3 mediated diseases and disorders

Publications (2)

Publication Number Publication Date
AU2003270540A8 AU2003270540A8 (en) 2004-04-30
AU2003270540A1 true AU2003270540A1 (en) 2004-04-30

Family

ID=31994030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270540A Abandoned AU2003270540A1 (en) 2002-09-11 2003-09-11 Treatment of cyclooxygenase-3 mediated diseases and disorders

Country Status (2)

Country Link
AU (1) AU2003270540A1 (en)
WO (1) WO2004024186A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489428A1 (en) 2002-06-27 2004-01-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
UA103955C2 (en) * 2009-11-05 2013-12-10 Алкем Леборетриз Лтд. Stable injectable pharmaceutical composition of aceclofenac and method of use thereof
EP3057386B1 (en) * 2015-02-13 2017-06-21 King Slide Works Co., Ltd. Slide rail assembly

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine

Also Published As

Publication number Publication date
WO2004024186A2 (en) 2004-03-25
AU2003270540A8 (en) 2004-04-30
WO2004024186A3 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
ZA200603174B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003268531A1 (en) Materials and methods for treatment of allergic diseases
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003258305A1 (en) Combination therapy for treatment of fibrotic disorders
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003291342A1 (en) Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
AU2003259706A1 (en) Therapeutic process for the treatment of obesity and associated metabolic disorders
AU2003270536A1 (en) Method of treating skin disorders
AU2003209150A1 (en) Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases
AU2002340465A1 (en) Cyclo(prolyl-glycine) and methods of use to treat neural disorders
AU2002243778A1 (en) Treatment of ppar mediated diseases
AU2003270540A1 (en) Treatment of cyclooxygenase-3 mediated diseases and disorders
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003222250A1 (en) Treatment of autoimmune diseases
AU2003256447A1 (en) Treatment of autoimmune skin diseases
AU2003270815A1 (en) Treatment of irritable bowel syndrome and related bowel diseases
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
AU2003301346A1 (en) Method of treating neurological diseases and disorders
AU2003297570A1 (en) Treatment of skin diseases
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2003254447A1 (en) Treatment of proliferative disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase